Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
146.47
-0.92 (-0.62%)
At close: Dec 20, 2024, 4:00 PM
147.65
+1.18 (0.81%)
After-hours: Dec 20, 2024, 6:13 PM EST
Biogen Revenue
Biogen had revenue of $2.47B in the quarter ending September 30, 2024, a decrease of -2.55%. This brings the company's revenue in the last twelve months to $9.61B, down -3.86% year-over-year. In the year 2023, Biogen had annual revenue of $9.84B, down -3.32%.
Revenue (ttm)
$9.61B
Revenue Growth
-3.86%
P/S Ratio
2.22
Revenue / Employee
$1,269,155
Employees
7,570
Market Cap
21.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Koninklijke Philips | 20.12B |
| Teva Pharmaceutical | 16.77B |
| Zimmer Biomet Holdings | 7.60B |
| STERIS | 5.33B |
| Illumina | 4.39B |
| Mettler-Toledo International | 3.76B |
| BioNTech SE | 3.39B |
| Waters | 2.91B |
BIIB News
- 8 days ago - Private Medicare plans must cover Biogen's ALS drug, US agency says - Reuters
- 11 days ago - Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown - Benzinga
- 16 days ago - GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners - Business Wire
- 17 days ago - Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript - Seeking Alpha
- 18 days ago - Biogen expects steady growth for Alzheimer's drug Leqembi in near term - Reuters
- 4 weeks ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 4 weeks ago - Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity - GlobeNewsWire
- 4 weeks ago - Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Benzinga